Funding
The clinical trial was supported, in part, by grants (to CHS) from the Vice President for Research at the University of Utah (Triple I Initiative), the Cell Therapy and Regenerative Medicine Program at the University of Utah, and the BioUtah CARES act for COVID.This study was also supported, in part, by the University of Utah Study Design and Biostatistics Center, with funding in part from the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 5UL1TR001067-02 (formerly 8UL1TR000105 and UL1RR025764).